Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Lyra Therapeutics, Inc.
LYRA · SEC Filings
website
27
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the...
Price
0.19
Market Cap
337.23 K
Float
1.63 M
Country
US
Sector
Healthcare
Exchange
OTC
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about LYRA
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Lyra Therapeutics, Inc.
LYRA · SEC Filings
1.63 M
Float
0.19
Price
337.23 K
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 31, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 6, 2025
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 13, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 12, 2024
News
TYPE
HEADLINE
FILED AT
8-K
Lyra Therapeutics Terminates Sublease for Waltham Facility
Apr 17, 2026
8-K
Lyra Therapeutics Announces Termination of Two Facility Leases
Apr 10, 2026
8-K
Lyra Therapeutics to be Delisted from Nasdaq
Mar 16, 2026
8-K
Lyra Therapeutics Receives Notice of Default on Sublease Amidst Company Wind-Down
Feb 27, 2026
8-K
Lyra Therapeutics Receives Nasdaq Delisting Notice
Feb 6, 2026
8-K
Lyra Therapeutics Announces Workforce Reduction and Strategic Shift
Jan 12, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B3
UPDATED | SHARE RESALE REGISTRATION | Shares amount: 846,744 | Share price: $11.81 | Warrants amount: 846,744 | Warrants exercise price: $11.56
Jul 30, 2025
424B5
REGISTERED OFFERING
Jun 27, 2025
424B5
June 2025 ATM | Amount sold to date: $24,835,145
Jun 26, 2025
424B5
ATM | Offering amount: $50,000,000
Sep 1, 2023
424B3
UPDATED
Jul 7, 2023
424B3
UPDATED
May 20, 2022
Registrations
TYPE
HEADLINE
FILED AT
S-8 POS
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Mar 25, 2026
S-8 POS
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Mar 25, 2026
S-8 POS
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Mar 25, 2026
S-8 POS
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Mar 25, 2026
S-8 POS
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Mar 25, 2026
POS AM
Form POS AM - Post-Effective amendments for registration statement
Mar 25, 2026
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 9, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 4, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 4, 2025
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Mar 25, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 29, 2024
Ownerships
TYPE
HEADLINE
FILED AT
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 27, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 27, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 27, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Jul 31, 2025
CORRESP
Form CORRESP - Correspondence
Jul 28, 2025
LETTER
Form UPLOAD - SEC-generated letter
Jul 28, 2025
